Regeneration + Anti-Inflammatory Stack
PreclinicalBPC-157 + TB-500 + GHK-Cu + KPV Stack
This four-peptide combination builds on the BPC-157 + TB-500 + GHK-Cu regeneration stack by adding KPV, a potent anti-inflammatory tripeptide derived from alpha-MSH. The rationale is to combine tissue repair (BPC-157, TB-500, GHK-Cu) with targeted inflammation control (KPV) through NF-κB inhibition. This stack is discussed in biohacking communities for comprehensive healing protocols, particularly for gut health and systemic inflammation alongside tissue repair. No research exists on this four-compound combination. Here is what the research shows for each component.
Science simplified
This stack adds an anti-inflammatory peptide (KPV) to the three-compound tissue repair stack. BPC-157 promotes blood vessel growth and healing signals. TB-500 helps cells move to injury sites. GHK-Cu activates collagen genes. KPV blocks NF-κB, a key driver of inflammation. The idea is that controlling inflammation while repairing tissue may improve outcomes. No study has tested these four together or any similar multi-peptide combination.
Best researched for
Each component individually · tissue repair · anti-inflammation
Evidence stage
Zero combination data · individual components L1–L3
Approval status
Not FDA-approved · investigational
0
Indexed Studies
Preclinical
Evidence Level
None
Human Trial Data
Research
Approval Status
PSI OVERVIEW
This is the most comprehensive repair and anti-inflammatory peptide combination discussed in the functional medicine space. It layers four mechanisms: BPC-157's multi-pathway healing, TB-500's actin-mediated cell migration, GHK-Cu's gene expression modulation, and KPV's direct NF-κB inhibition. The pharmacological logic is interesting — you are essentially addressing tissue repair from three angles while simultaneously suppressing the inflammatory cascade that can impede healing. PSI rates this combination L1. The individual evidence ranges from L1 (KPV) to L3 (BPC-157). The combination itself has zero published data. Combining four investigational compounds multiplies the unknowns. Each component should be evaluated independently.
Mechanism of Action
In everyday terms: Think of this as four specialized repair crews. BPC-157 brings blood supply and growth signals. TB-500 helps cells physically move to the injury. GHK-Cu tells genes to produce repair proteins. KPV turns down the inflammation that can slow healing. Each works through a completely different pathway. Whether having all four working simultaneously helps more than one or two alone has never been tested.
The four components target distinct biological pathways. BPC-157 promotes angiogenesis through VEGF upregulation and modulates the nitric oxide system. TB-500 regulates actin polymerization via the LKKTET motif, enabling cell migration. GHK-Cu modulates expression of over 4,000 genes involved in tissue remodeling. KPV (Lys-Pro-Val) is a C-terminal fragment of alpha-MSH that directly inhibits NF-κB, the master transcription factor controlling inflammatory gene expression.
What is this stack being studied for?
No study has tested this combination. Evidence ratings reflect the stack as a whole (L1). See individual compound pages for component-level evidence.
Comprehensive Tissue Repair
PreclinicalThree repair peptides (BPC-157, TB-500, GHK-Cu) plus an anti-inflammatory (KPV). The theory is that reducing inflammation while promoting repair creates a more favorable healing environment. Entirely untested as a combination.
Gut Healing with Inflammation Control
PreclinicalBPC-157 has the strongest individual gut healing data (L3). KPV has preclinical data for reducing intestinal inflammation via NF-κB inhibition and oral bioavailability. The combination for gut applications is anecdotal.
Post-Surgical or Injury Recovery
PreclinicalThe most commonly discussed use case in biohacking communities. The rationale combines structural repair (TB-500, GHK-Cu), multi-pathway healing (BPC-157), and inflammation control (KPV). Zero clinical data.
Systemic Inflammation
PreclinicalKPV targets NF-κB directly. BPC-157 and GHK-Cu both have anti-inflammatory properties through different mechanisms. Whether four anti-inflammatory signals are additive or redundant is unknown.
PSI Verdict
Supported by evidence
Each component has independent evidence: BPC-157 (L3, 212 studies), TB-500 (L2, 1,050 studies), GHK-Cu (L2, 186 studies), KPV (L1, 27 studies). The mechanisms are distinct and complementary. The concept of pairing repair with anti-inflammatory signaling is pharmacologically rational.
Not yet established
Whether four compounds produce superior outcomes to fewer. Whether the components interact when co-administered. The safety profile of a four-peptide combination — complexity increases uncertainty exponentially. Whether KPV adds meaningful benefit beyond the anti-inflammatory effects already present in the other three components. No published research exists on any 3- or 4-compound peptide combination stack.
Stack Components
Molecular data for each component.
Research Evidence
No published research exists on this four-compound combination or any similar multi-peptide stack. The evidence below summarizes what is known about each component individually and the theoretical rationale for combining them.
BPC-157 has 212+ indexed studies showing consistent tissue repair across tendons, ligaments, gut, and liver in animal models
The strongest individual evidence base in this stack. L3 reflects limited but existing human data.
TB-500 has 1,050+ indexed studies documenting actin regulation, cell migration, and wound healing
Extensive basic science. L2 reflects the absence of controlled human trials for systemic use.
GHK-Cu modulates expression of over 4,000 human genes involved in tissue remodeling
Unique gene expression modulation mechanism. L2 reflects strong mechanistic data with limited clinical translation.
KPV directly inhibits NF-κB, the master transcription factor for inflammatory gene expression
27 indexed studies. L1 reflects very limited research volume. Anti-inflammatory mechanism is well-characterized at the molecular level.
Zero published studies test any combination of these compounds
This is the single most important fact. No 2-, 3-, or 4-compound peptide stack has been evaluated in published research.
Safety Profile
No safety data exists for this four-compound combination. Combining four investigational compounds increases pharmacological complexity and uncertainty about interactions. BPC-157, TB-500, GHK-Cu, and KPV were all placed on the FDA's Category 2 restricted list and are expected to return to Category 1. The combination product has no separate regulatory status. More compounds means more unknowns.
Comparison: Complexity Ladder
More compounds does not automatically mean better outcomes. This comparison shows how evidence quality decreases and complexity increases as you add compounds. The simplest option with the strongest evidence may be the most rational starting point.
Frequently Asked Questions
Questions to Ask Your Doctor
If you are considering discussing this combination with a healthcare provider, these questions can help start an informed conversation.
Explore Related Research
Side-by-side research comparisons with related compounds.
How to Choose
Decision guidance based on existing evidence — not a recommendation.
Looking for a physician experienced with peptide therapy?
Every physician in the PSI directory is individually verified for active licensure, board certification, and clinical peptide experience.
Browse the PSI Physician DirectoryMedical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.